A key new coronary immunology study has revealed encouraging news for COVID-19 survivors,media BGR reported. Scientists studying COVID-19 immunity have determined that T-cell responses with strong cellular memory of the new coronavirus can be detected for at least six months in new crown patients who have experienced asymptomatic and mild illness and do not require hospitalization. This immunology study brings good news for vaccine research, as many vaccines should also induce a reaction between antibodies and T-cells.
Recent COVID-19 immunology studies are not all promising. Scientists from the UK have found that some new coronavirus antibodies can disappear within two to three months. The study looked at the general population, and the researchers used random subjects at each stage of the test. All other immunology studies have brought very promising news. A paper from Iceland explains some of the unreliable antibody tests, and it is likely that people who survive the infection will have detectable antibodies for at least four months after infection. Two independent studies from the United States have made similar estimates for meso-antibodies: at least 5-7 months or at least 5 months. And now, a whole new paper brings us good news about the new coronavirus immunity. Different COVID-specific parts of the immune system do not appear in antibody testing for at least 6 months.
Researchers from Public Health England and the Uk Coronavirus Immunology Alliance (UK-CIC) studied T-cell responses in 100 COVID-19 survivors. T cells are a key component of the immune system. They are white blood cells involved in responding to various pathogens, not just the new coronavirus. These are not antibodies, and testing of T-cells is not easy. But they are the kind of immune component that lasts longer than antibodies. What’s more, these cells can “remember” the new coronavirus and “call out an extra army of antibodies” when they encounter the same pathogen again.
The researchers found that the T cells they tested had specific reactions to various coronavirus proteins, Bloomberg reported. The list includes the most important protein in vaccine research, the pyrethroids that bind to cells, allowing the virus to enter the only place where it can reproduce.
The researchers found that after six months, the T-cell response was “strong.” Those who experienced symptoms had at least 50 percent higher levels than those who did not. The study included asymptomatic and mild patients who were not hospitalized for COVID-19 treatment. The study found that those with symptoms had levels of at least 50 percent.
“As far as we know, our study is the first in the world to show that strong cellular immunity remains in individuals experiencing mild/moderate or asymptomatic COVID-19 six months after infection,” UK-CIC Lead Professor Paul Moss said in a statement. “Interestingly, we found that those with symptomatic infections had stronger cellular immunity at this point in time than in asymptomatic cases. We now need to do more research to see if people with symptoms can better protect themselves from re-infection in the future. “
Researchers will continue to study the patient’s immunity and determine the duration of the immune response. Some vaccine leaders have shown that they can replicate this dual immune response (between antibodies and T-cells). It is hoped that this protection will last for at least six months.